ʻO ka mālama ʻana i ka maʻi maʻi ʻaʻai ʻo Kina 2026: ʻO nā lāʻau lapaʻau a me nā kumukūʻai hou loa - nā halemai kokoke iaʻu 

Ka ma'i 'a'ai ma ke ake, he ma'i ma'i ma'i hepatocellular (HCC), he ma'i ma'i ma'i mai loko mai o nā pūna'i ake e koi 'ia ai ke komo 'ana i ka multidisciplinary. I ka makahiki 2026, ua puka mai ʻo Kina ma ke ʻano he alakaʻi honua i ka mālama ʻana i ka maʻi maʻi ʻaʻai, e hāʻawi ana i nā hui immunotherapy ʻokiʻoki, nā ʻenehana hana holomua e like me ka robotic hepatectomy, a me nā kikowaena mālama piha ma Beijing. Loaʻa i nā poʻe maʻi e ʻimi nei i ka lāʻau lapaʻau hou e like me Lenvatinib i hui pū ʻia me TACE a me ka novel PD-1 inhibitors, e hoʻomaikaʻi nui ana i nā helu ola a me ka mālama ʻana i nā maʻi i hoʻohālikelike ʻia i nā makahiki i hala.

Ka hoʻomaopopo ʻana i ka maʻi maʻi i loko o ke ake: ʻano a me nā kumu pilikia

Ke kūkākūkā ka ma'i 'a'ai ma ke ake, he mea koʻikoʻi ka hoʻokaʻawale ʻana ma waena o nā ʻano kumu mua a me nā ʻano lua. Hoʻomaka ka maʻi ʻaʻai mua ma loko o ke ake ponoʻī, me ka Hepatocellular Carcinoma (HCC) ka helu no ka hapa nui o nā hihia. ʻO ka maʻi maʻi ate lua, a i ʻole ka maʻi maʻi metastatic, laha i ke ake mai nā ʻāpana ʻē aʻe e like me ke kolonā a i ʻole ka umauma. ʻOkoʻa loa nā protocols lapaʻau ma muli o kēia ʻokoʻa.

Hoʻopili pinepine ʻia ka ulu ʻana o ka maʻi maʻi ate mua i nā maʻi o ka ate. ʻO nā pūʻulu pilikia nui ka poʻe ma mua o 40 mau makahiki, ʻoi aku ka nui o nā kāne, a me nā wahine ma luna o 50 i loaʻa ka moʻolelo o ka maʻi Hepatitis B a i ʻole C. ʻO ka ʻai ʻana i ka waiʻona lōʻihi, ka maʻi diabetes, a me ka mōʻaukala ʻohana o ka maʻi ʻaʻai aʻe e hoʻokiʻekiʻe loa i nā pae pilikia.

• ʻO nā maʻi hepatitis: ʻO ka maʻi maʻi maʻi me ka Hepatitis B (HBV) a i ʻole Hepatitis C (HCV) ke kumu nui ma ka honua a ma Kina.
• Cirrhosis: ʻO ka ʻili ʻana o ka ʻiʻo o ke ake mai kekahi kumu e hoʻonui ai i ka hiki ke hoʻololi kino.
• Nā kumu o ke ola: Ke piʻi aʻe nei ka hoʻohana ʻana i ka waiʻona nui a me nā maʻi metabolic e like me non-alcoholic fatty liver disease (NAFLD).
• Nā meaʻawaʻawa kaiapuni: ʻO ka ʻike ʻana i nā aflatoxins i loaʻa i loko o nā ʻōpala polū hiki ke kōkua i ka hoʻololi ʻana o ka genetic i loko o nā pūnaʻi ate.

ʻO ka ʻike mua ke kumu koʻikoʻi loa no nā hopena kūleʻa. Manaʻo nā alakaʻi lapaʻau e hoʻopaʻa ʻia ka poʻe pilikia nui i kēlā me kēia ʻeono mahina. Hoʻopili maʻamau kēia i ke kiʻi ultrasound a me nā hoʻāʻo koko no nā pae alpha-fetoprotein (AFP). ʻO ka ʻike mua ʻana e hiki ai i nā koho curative e like me ka ʻoki ʻoki ʻana a i ʻole ka hoʻololi ʻana i ke akepaʻa, ʻoiai ʻo ka maʻi hope loa e kaupalena ʻia ka mālama ʻana i ka mālama palliative a i ʻole ka ʻōnaehana systemic.

ʻO nā halemai kiʻekiʻe no ka mālama ʻana i ka maʻi maʻi ate ma Beijing 2026

Ke lawelawe nei ʻo Beijing ma ke ʻano he kauka lapaʻau no Kina, e hoʻokipa ana i kekahi mau ʻoihana papa honua i loea i ka hepatobiliary oncology. No nā poʻe maʻi o ka honua a me ka home e ʻimi nei i ka mālama maikaʻi loa ka ma'i 'a'ai ma ke ake, ʻekolu mau halemai ma ke kūlana kiʻekiʻe ma muli o ko lākou mau mana piha, ka hoʻopuka noiʻi, a me ka ʻike loea.

Halemai Kolepa Lapaʻau Lapaʻau ʻo Peking Union (PUMCH)

ʻO ka Chinese Academy of Medical Sciences Peking Union Medical College Hospital i manaʻo nui ʻia ʻo ia ke kumu mua no nā hihia paʻakikī. Kaulana ʻia kāna ʻoihana ʻoki ʻana no ka mālama ʻana i nā hihia koʻikoʻi a paʻakikī i manaʻo ʻia ʻaʻole hiki ke hana ʻia nā kikowaena ʻē aʻe. Aia ka haukapila i ka pae mua ma ka ʻāina i ka lāʻau mālama koʻikoʻi, he mea nui ia no ka hoʻihoʻi hou ʻana ma hope o ka hana ʻana i ka ʻoki ʻana.

Hāʻawi ka PUMCH i kahi hui multidisciplinary hui piha (MDT). ʻO kēia ke ʻano o nā kauka lapaʻau, oncologists, radioologists, a me nā pathologists e hui pū i kēlā me kēia hihia e hoʻolālā i kahi hoʻolālā lapaʻau pilikino. Hāʻawi ka hale hana ma luna o 2,000 mau moena hāmama a paʻa i ka hoʻopaʻa inoa ʻana ma ke ʻano he kikowaena kūikawā koʻikoʻi i loko o nā ʻāpana pae ʻehiku. ʻIke ʻia ko lākou kūpaʻa ʻana i ka hoʻonaʻauao hoʻomanawanui ma o ka nui o nā hana hoʻolaha ʻepekema ʻepekema.

Halemai PLA Nui Kina (301 Halemai)

ʻO ka Halemai PLA Nui Kina, ʻo ia hoʻi kāna Keʻena ʻo Hepatobiliary a me Pancreatic Surgery, he hale mana i ka hana hou ʻana. Hoʻonoho ʻia ʻo ia i ke kolu o ka ʻāina i ka hana o ka haukapila holoʻokoʻa, he alakaʻi ia i ka hoʻololi ʻana o ka ate a me nā ʻokiʻoki paʻakikī. Ke alakaʻi ʻia nei ka ʻoihana e nā poʻe loea koʻikoʻi me nā makahiki he ʻumi o ka ʻike i ka mālama ʻana i nā maʻi maʻi ʻino o ka ʻōnaehana hepatobiliary.

ʻO kēia keʻena he hale hoʻokolohua lāʻau lapaʻau i koho ʻia (GCP), e ʻae ana i nā poʻe maʻi e komo i nā hoʻokolohua lapaʻau Phase II a me III no nā lāʻau lapaʻau hou. Ua hoʻokumu ʻo ia i ka launa pū ʻana me ke Kulanui o Pittsburgh Medical Center (UPMC), e hoʻomaʻamaʻa i ka hoʻololi ʻana i nā ʻano hana ʻokiʻoki kiʻekiʻe a me nā protocols lapaʻau. Hāʻawi pū ka haukapila i kahi kikowaena noiʻi olakino e hoʻohana ana i nā ʻōnaehana diagnostic kōkua AI e hoʻomaikaʻi i ka pololei.

Halema'i Kanaka o ke Kulanui o Peking

Hāʻawi ʻo Peking University People's Hospital i kahi mālama kūikawā ma o kāna Keʻena ʻOihana Hepatobiliary. He kūlana kiʻekiʻe loa ma ka ʻāina ʻo Kina ʻĀkau, ua hoʻohui ʻo ia i ka maikaʻi o ka hana kuʻuna me nā ʻōnaehana ʻōnaehana hou. ʻO ka haukapila kahi papa kula kiʻekiʻe Grade A me ka inoa ʻinikua lapaʻau, hiki ke loaʻa iā ia no ka lehulehu o nā maʻi.

E like me kona mau hoa, hoʻoikaika ia i kahi hiʻohiʻona MDT a hāʻawi i nā keʻena kūikawā e like me ke ʻoki ākea, ka oncology piha, ka lāʻau lapaʻau Kina kuʻuna, a me ka radiotherapy. ʻO kēia laula o nā lawelawe e hōʻoia inā makemake ka mea maʻi i ka hoʻomaʻemaʻe liʻiliʻi, ka chemotherapy ikaika, a i ʻole ka mālama TCM kākoʻo, loaʻa nā lawelawe āpau ma lalo o hoʻokahi hale.

ʻApono ʻia nā lāʻau lapaʻau Breakthrough a me nā lāʻau lapaʻau ma 2026

ʻO ka ʻāina o ka mālama ʻana ka ma'i 'a'ai ma ke ake ua neʻe nui i ka makahiki 2026 me ka ʻae ʻia o kekahi mau lāʻau lapaʻau groundbreaking. Ua neʻe ka manaʻo mai nā lāʻau lapaʻau hoʻokahi-agent i nā regimens hui e hoʻopaʻa i nā ala he nui i ka manawa like, e hopena i nā helu pane kiʻekiʻe a me ke ola lōʻihi.

Hoʻohui ʻia ʻo Lenvatinib me TACE a me Immunotherapy

Ua loaʻa kahi milestone nui i Iulai 2025, me ka hoʻokō piha ʻana i 2026, e pili ana i ka ʻae ʻia o Lenvatinib (Lenvima®). Ua ʻae ʻia kēia mea hoʻopaʻapaʻa tyrosine kinase kinase (TKI) oral waha no kahi hōʻailona hou: hui pū ʻia ʻo Lenvatinib me Pembrolizumab a me Transarterial Chemoembolization (TACE). ʻO kēia "TACE + Targeted + Immune" triplet regimen ʻo ia ka mea mua o kona ʻano ma ka honua i ʻae ʻia no ka HCC non-metastatic hiki ʻole ke hoʻololi ʻia.

Ua hōʻike ʻia nā ʻikepili lapaʻau mai ka haʻawina Phase III LEAP-012 i ka maikaʻi. Ua loaʻa i ka hui hui pūʻulu i kahi 24 mau mahina holoʻokoʻa ola (OS) helu o 75%, ʻoi aku ka nui o ka pūʻulu mana. Eia kekahi, ua hoʻonui ʻia ka median progression-free survival (PFS) i 14.6 mau mahina, kahi hoʻomaikaʻi nui ma luna o nā mahina 10.0 i ʻike ʻia i nā hui mālama maʻamau. ʻO kēia regimen kahi koho maʻamau no nā poʻe maʻi ʻaʻole hiki ke wehe ʻia nā maʻi koko akā ʻaʻole i laha i nā ʻōpū mamao.

Finotonlimab a me Bevacizumab Hui

ʻO kekahi holomua pivotal ka ʻae ʻana o Finotonlimab (SCT-I10A), kahi antibody monoclonal anti-PD-1 i kūkulu ʻia i loko. I ka hoʻomaka ʻana o 2025, ua ʻae ʻia no ka hoʻohana pū ʻana me Bevacizumab (SCT510) no nā poʻe maʻi me ka HCC unresectable a i ʻole metastatic i loaʻa ʻole i ka mālama ʻōnaehana ma mua. Kuhi ʻia kēia lāʻau ʻelua i ka helu PD-1 a me ka vascular endothelial growth factor (VEGF).

Hōʻike ka ʻikepili honua maoli a me nā hoʻokolohua lapaʻau i kahi Objective Response Rate (ORR) o 33% no kēia hui ʻana, ʻoi aku ka kiʻekiʻe ma mua o ka 4% i ʻike ʻia i nā pūʻulu mana. Ua ʻike ka poʻe maʻi i ka hōʻemi ʻana o 50% i ka hopena o ka piʻi ʻana o ka maʻi, me ka PFS median o 7.1 mau mahina. ʻO ka mea nui loa, ʻo ka median ola holoʻokoʻa i hiki i 22.1 mau mahina, e hōʻemi ana i ka hopena o ka make ma 40% i hoʻohālikelike ʻia i nā kūlana mua. Hāʻawi kēia i ka manaolana hou no nā poʻe maʻi me ka maʻi pae kiʻekiʻe.

ʻO ka "O + Y" Dual Immunotherapy Regimen

ʻO ka hui pū ʻana o Nivolumab (Opdivo®) a me Ipilimumab (Yervoy®), i kapa ʻia ʻo "O + Y" regimen, ua paʻa i kona kūlana ma ke ʻano he lāʻau lapaʻau mua no ka HCC unresectable. Ua ʻae ʻia ma Kina i ka hoʻomaka ʻana o 2025, ua hoʻokaʻawale ʻia kēia ʻelua ʻāpana hoʻopaʻa hoʻopaʻa i nā ala PD-1 a me CTLA-4. He mea maikaʻi loa ia no nā poʻe maʻi i ʻae ʻole i nā hopena ʻaoʻao TKI a i ʻole i loaʻa i nā biomarkers tumor kikoʻī.

Hōʻike kēia regimen i ka neʻe ʻana i nā koho chemotherapy-free no ka maʻi maʻi ate. Ma ka hoʻokuʻu ʻana i ka ʻōnaehana pale ponoʻī o ke kino e hoʻouka i nā maʻi maʻi maʻi mai ʻelua ʻaoʻao like ʻole, hiki iā ia ke hoʻoulu i nā pane paʻa i loko o kahi ʻāpana o nā maʻi, ʻo kekahi o lākou e loaʻa i ke kala lōʻihi. ʻO ka loaʻa ʻana o kēia lāʻau lapaʻau ma nā halemai Beijing nui e hōʻoia i ka loaʻa ʻana o nā mea maʻi Kina i nā immunotherapies ʻoki ʻoki like i loaʻa ma US a me ʻEulopa.

Loaʻa nā ʻano lapaʻau piha ma Kina

Ka mālama ʻana ka ma'i 'a'ai ma ke ake i ka makahiki 2026 ʻaʻole hiki ke ʻano like ʻole. Hoʻohana nā keʻena lapaʻau Kina i kahi hoʻolālā multimodal, e hoʻopili ana i ka hana i ka pae o ka maʻi kanesa, ka hana o ke ake i koe, a me ke olakino holoʻokoʻa o ka mea maʻi. ʻO ke kūlana o ka mālama mālama ʻana i kēia manawa ke kākoʻo nei i kahi hoʻohālike Multidisciplinary Team (MDT).

ʻO ka ʻoki ʻana a me ka hoʻololi ʻana i ke ake

ʻO ka ʻokiʻoki wale nō ka lāʻau lapaʻau hiki ke hoʻōla ʻia no ka maʻi maʻi ʻaʻai mua. ʻO ka ʻoki ʻoki ʻana e pili ana i ka wehe ʻana i ke koko a me ka palena o ka ʻiʻo olakino. ʻO nā holomua i ka ʻoki ʻana robotic a me nā ʻenehana laparoscopic ua hōʻemi i nā manawa hoʻōla a me nā pilikia. No nā poʻe maʻi me ka maʻi maʻi maʻi mua me ka cirrhosis koʻikoʻi, ʻo ka hoʻololi ʻana i ka ate ke koho i makemake ʻia, no ka mea, wehe ʻia ka ʻōpū a me ke ake maʻi.

I ka makahiki 2026, ua hoʻomaʻemaʻe ʻia nā koina no ka hoʻololi ʻana e hoʻokomo i nā protocol down-stage. Hiki i nā poʻe maʻi ma waho o nā pae hoʻololi ke hele i nā lāʻau lapaʻau locoregional e hōʻemi i nā maʻi maʻi, e hiki ai iā lākou ke hoʻololi. Hana nā kikowaena nui ma Beijing i nā haneli o kēia mau kaʻina hana paʻakikī i kēlā me kēia makahiki me nā helu lanakila kiʻekiʻe.

Nā lāʻau lapaʻau hoʻopau kūloko

No nā ʻōpū liʻiliʻi (ʻoi aku ka liʻiliʻi ma mua o 3 knm) ʻaʻole kūpono no ka ʻoki ʻana, ʻo ka ablation kūloko kahi koho ʻoi loa. Aia kēia me Radiofrequency Ablation (RFA) a me Microwave Ablation (MWA). Hoʻohana kēia mau kaʻina hana hoʻoweliweli liʻiliʻi i ka wela e hoʻopau pololei i nā maʻi kanesa. Hoʻohana pinepine ʻia ia mau mea ma lalo o ke alakaʻi kiʻi, koi wale i kahi noho maʻi pōkole.

Hoʻohana nui ʻia ka Ablation me nā lāʻau lapaʻau ʻē aʻe. No ka laʻana, hiki ke hoʻohana ʻia e mālama i ke koena o ka maʻi ma hope o TACE a i ʻole e mālama i ka hoʻihoʻi hou ʻana i nā maʻi i loaʻa mua i ka resection. ʻO ka pololei o ke kiʻi kiʻi hou e hiki ai i nā kauka ke kuhikuhi i nā maʻi maʻi ʻoiai e mālama ana i ka parenchyma ate olakino.

ʻO ka Chemoembolization Transarterial (TACE)

Noho mau ʻo TACE i ka maʻamau o ka mālama ʻana no ka maʻi maʻi ʻaʻai waena waena. ʻO kēia kaʻina hana e hoʻokomo pololei i nā lāʻau chemotherapy i loko o ke aʻa e hānai ana i ka ʻōpū, a ukali ʻia e nā mea embolic e pale i ke kahe koko. ʻO kēia "pōloli" i ke koko o ka oxygen a me nā meaʻai i ka wā e hāʻawi ana i kahi kiʻekiʻe o nā lāʻau lapaʻau ma ka'āina.

ʻO ka ulu ʻana o TACE ma 2026 e pili ana i kona hoʻohui ʻana me nā ʻōnaehana systemic. E like me ka mea i hōʻike ʻia me ka ʻae ʻana o Lenvatinib, ʻaʻole ʻo TACE kahi silo kūʻokoʻa akā he ʻāpana o kahi hoʻolālā ʻōnaehana ākea. Ua hoʻomaikaʻi ʻia ka maikaʻi a me ka palekana o kēia kaʻina hana i nā peʻa lāʻau lapaʻau a me nā mea embolic hou, e hōʻemi ana i nā hōʻailona post-embolization syndrome.

ʻO ka lāʻau hoʻomaʻamaʻa a me ka hoʻoheheʻe ʻana

No ka ma'i pae ki'eki'e, 'o ka systemic therapy ka pōhaku kihi o ka lā'au lapa'au. Hoʻopili kēia i ka lāʻau lapaʻau i hoʻopaʻa ʻia (TKI), immunotherapy (nā mea hoʻopaneʻe nānā), a me ka chemotherapy i kekahi manawa. Ua hoʻonui nui ʻia ka arsenal o nā lāʻau lapaʻau, e ʻae ana i nā laina sequential o ka lāʻau lapaʻau inā hāʻule ka laina mua.

ʻO ka lāʻau lapaʻau, ʻo ia hoʻi ʻo Stereotactic Body Radiation Therapy (SBRT) a me Proton Beam Therapy, ke pāʻani nei i kahi hana koʻikoʻi. Hāʻawi kēia mau ʻenehana i nā kiʻekiʻe kiʻekiʻe o ka radiation me ka pololei loa, e hōʻemi ana i ka pōʻino i ka ʻiʻo o ke ake olakino a puni. He mea maikaʻi loa ia no nā maʻi koko e kokoke ana i nā kīʻaha koko nui a i ʻole no nā maʻi me ka portal vein thrombosis.

Ka helu ʻana i ke kumu kūʻai: Nā lilo lapaʻau ma 2026

ʻO ka hoʻomaopopo ʻana i nā hopena kālā he ʻāpana koʻikoʻi o ka huakaʻi maʻi. ʻO ke kumukūʻai o ka mālama ʻana ka ma'i 'a'ai ma ke ake ma Kina, ʻokoʻa ka nui ma muli o ke ʻano o ka maʻi, ke ʻano o ka mālama ʻana i koho ʻia, a me ka lōʻihi o ka mālama ʻana. ʻOiai hiki ke koʻikoʻi nā kumukūʻai, ʻo ka hoʻokomo ʻana i nā lāʻau lapaʻau hou i loko o nā papahana ʻinikua olakino ua hoʻomaikaʻi ʻia ka hiki.

Na koina o ke kino

No nā poʻe maʻi ma mua o ka hoʻopau ʻana i ka ʻokiʻoki, ʻo ka nui o ke kumukūʻai maʻamau mai 50,000 a 150,000 RMB. Hoʻopili kēia kuhi i nā hoʻokolohua pre-operative, ke kaʻina hana ʻoki ponoʻī, anesthesia, a me ka hale hoʻokipa. ʻO nā hihia paʻakikī e koi ana i ka noho ICU lōʻihi a i ʻole ka hoʻokele ʻana i nā hoʻopiʻi hiki ke ʻoi aku ma mua o kēia pae.

ʻO ka hoʻololi ʻana i ke ake, ʻo ia ke koho ʻokiʻoki ʻoi loa. ʻOi aku ke kumu kūʻai no ke kaʻina hana ma mua o 200,000 RMB. Eia nō naʻe, i ka helu ʻana i ka lāʻau immunosuppressive lōʻihi a me ka mālama ʻana, hiki ke ʻoi aku ka nui o ke kumukūʻai o ke ola ma mua o 800,000 RMB. ʻOiai ke kiʻekiʻe o ka hoʻopukapuka mua, hāʻawi ka transplantation i ka manawa maikaʻi loa no ke ola lōʻihi i nā moho kūpono.

Nā kumukūʻai hoʻoponopono a me ka Locoregional Therapy

ʻOi aku ka maʻalahi o nā kaʻina hana e like me TACE i kēlā me kēia kau, ke kumu kūʻai ma waena o 10,000 a me 30,000 RMB. Eia naʻe, koi pinepine ka maʻi ʻaʻai i nā kau he nui i ka manawa, e hōʻiliʻili ana i nā kumukūʻai. No nā poʻe maʻi me nā pilikia cirrhosis e like me ka ascites a i ʻole ke kahe ʻana o ka ʻōpū, hiki i ka halemai no ka mālama kākoʻo mai 10,000 a 50,000 RMB no ke komo ʻana.

Hāʻule nā lāʻau lapaʻau Ablation i loko o kahi bracket kumu kūʻai like me TACE, pinepine mai ka 15,000 a 30,000 RMB i kēlā me kēia kau ma muli o ka ʻenehana i hoʻohana ʻia (e like me ka microwave vs. radiofrequency) a me ka helu o nā maʻi koko i mālama ʻia.

ʻO ke kumu kūʻai o ka lāʻau lapaʻau

ʻO ke kumukūʻai o ka systemic therapy he mea kaumaha ma mua, akā ke loli nei ka ʻāina. Hiki i nā poʻe maʻi hope loa e hoʻohana ana i nā lāʻau lapaʻau e like me Sorafenib a i ʻole immunotherapies hou ke kū i nā kumukūʻai makahiki mai 200,000 a 500,000 RMB inā e uku ana i waho o ka ʻeke. Hiki ke kūʻai ʻia kekahi mau mea kūʻai aku ma mua o 30,000 RMB i kēlā me kēia mahina.

Eia nō naʻe, ua hoʻokomo ʻia ka nui o kēia mau lāʻau lapaʻau, me Lenvatinib a me nā mea hoʻopiʻi PD-1 like ʻole, i loko o ka National Reimbursement Drug List (NRDL) o Kina. ʻO kēia hoʻokomo ʻana e hoʻemi nui i ka lilo o waho o ka pocket no nā maʻi i hoʻopaʻa ʻia, i kekahi manawa e hoʻohaʻahaʻa i ke kumukūʻai o kēlā me kēia mahina i kahi mau tausani RMB. ʻOkoʻa nā kumukūʻai o ka radiation radiation e ka ʻenehana, me ka radiation maʻamau e kūʻai ana he 20,000 a 50,000 RMB, aʻo ka holomua proton therapy hiki ke ʻoi aku ma mua o 100,000 RMB i kēlā me kēia papa.

ICU a me nā lilo mālama koʻikoʻi

No nā poʻe maʻi me ka maʻi ate hope a i ʻole ka hemahema o ka ate, pono pinepine ka mālama koʻikoʻi. ʻO nā kumukūʻai o kēlā me kēia lā i ka ICU hiki ke piʻi mai 3,000 a 5,000 RMB. Hoʻohui ʻia nā lāʻau lapaʻau kūikawā e like me ka hoʻololi plasma a i ʻole nā ​​​​pūnaewele kākoʻo o ke akepaʻa i ka bila, me nā kau hoʻokahi e kūʻai ana ma luna o 10,000 RMB. Hōʻike kēia mau kumukūʻai i ke koʻikoʻi o ka ʻike mua ʻana a me ka hana ʻana e pale i ka piʻi ʻana i nā pae koʻikoʻi.

Ka Hoʻohālikelike Hoʻohālikelike o nā Kūlana Lapaʻau

ʻO ke koho ʻana i ke ala lapaʻau kūpono e pili ana i ka loiloi akahele o nā pono a me nā palena. Hōʻike ka hoʻohālikelike ma lalo nei i nā hoʻolālā mua i loaʻa no ka hoʻokele ka ma'i 'a'ai ma ke ake i ke kahua lapaʻau o kēia manawa.

Loaʻa i kēlā me kēia ʻano ʻano nā mea maikaʻi. Hāʻawi ka ʻokiʻoki i ka manawa kiʻekiʻe loa o ka hoʻōla akā lawe i nā pilikia o ke kaʻina. He palekana a maikaʻi ka hoʻomaʻemaʻe ʻana no nā liona liʻiliʻi akā ʻoi aku ka liʻiliʻi no nā ʻōpū nui. Mālama ʻo TACE i ka ulu ʻana o ka maʻi maʻi ma nā pae waena akā ʻaʻole hiki ke hoʻōla iā ia iho. Ua hoʻololi nā ʻōnaehana systemic i ka mālama ʻana i nā maʻi holomua, e hoʻohuli ana i kahi maʻi maʻi i hoʻokahi manawa i kahi maʻi maʻi maʻi no ka lehulehu.

Pono e kaupaona ʻia nā hemahema. Pono ka ʻoki ʻana a me ka hoʻololi ʻana i ka manawa hoʻōla nui a lawe i ka pilikia o ke koko a i ʻole ka maʻi. ʻAʻole hiki i ka Ablation ke hoʻopau loa i nā maʻi maʻi nui, e alakaʻi ana i ka hoʻi hou ʻana. Hiki i ka TACE ke hoʻoulu i ka maʻi post-embolization (ke kuni, ka ʻeha, ka nausea). Hiki i nā lāʻau lapaʻau ʻōnaehana ke hoʻoulu i nā hanana ʻino e pili ana i ka immune a i ʻole ke kiʻekiʻe a me nā ʻili lima wāwae mai nā TKI.

Ke alakaʻi i kēlā me kēia ʻanuʻu i ka ʻimi ʻana i ka lapaʻau ma Beijing

No nā poʻe maʻi e hoʻolālā e ʻimi i ka lāʻau lapaʻau ka ma'i 'a'ai ma ke ake ma Beijing, he mea nui ka hoʻokele ʻana i ka ʻōnaehana mālama ola kino. Hōʻike nā ʻanuʻu ma lalo i ke kaʻina hana maʻamau mai ka kūkākūkā mua ʻana a hiki i ka hoʻomaka ʻana o ka mālama ʻana.

• KaʻAnuʻu 1: E hōʻiliʻili i nā moʻolelo lapaʻau: E hōʻuluʻulu i nā palapala lapaʻau āpau e loaʻa nei, e like me ka scan imaging (CT, MRI), nā hōʻike pathology, nā hopena hoʻāʻo koko (ʻoi aku ka AFP a me nā hoʻāʻo ʻana i ka hana ate), a me kahi hōʻuluʻulu o nā lapaʻau mua. Paipai nui ʻia nā kope kikohoʻe ma ka USB drive a i ʻole ka loulou kapua.
• KaʻAnuʻu 2: E koho i kahi Halemai a me ka 'Oihana: E koho i kahi haukapila kiʻekiʻe e like me PUMCH, PLA General Hospital, a i ʻole ka Halemai Kanaka o ke Kulanui o Peking. E ʻike i ke keʻena kikoʻī, maʻamau ka Hepatobiliary Surgery, Oncology, a i ʻole Interventional Radiology, ma muli o ke kahua i manaʻo ʻia.
• KaʻAnuʻu 3: Koho inoa: E hoʻopaʻa inoa no kahi manawa ma o ka polokalamu oihana o ka haukapila, pūnaewele, a ma o kahi lawelawe concierge lapaʻau. No nā maʻi maʻi honua, ua hoʻolaʻa nā halemai he nui i nā keʻena lapaʻau honua e kōkua i nā pale ʻōlelo a me ka logistic.
• KaʻAnuʻu Hana 4: Kūkākūkā mua a me MDT Review: E hele i ke kūkākūkā kahi e nānā ai nā loea i kāu hihia. Ma nā halemai kiʻekiʻe, kūkākūkā pinepine ʻia nā hihia paʻakikī i kahi hālāwai MDT e pili ana i nā kaukaʻi, oncologists, a me radiologists e hana i kahi hoʻolālā lapaʻau hui.
• KaʻAnuʻu 5: Hoʻāʻo hou aku: E mākaukau no nā hoʻokolohua hou e hoʻohou i kou kūlana. Hiki i kēia ke komo i ka MRI i hoʻonui ʻia, PET-CT, a i ʻole ka hoʻāʻo genetic e hoʻoholo ai i ke kūpono no nā lāʻau lapaʻau kikoʻī a i ʻole nā ​​hoʻokolohua lapaʻau.
• KaʻAnuʻu 6: Hoʻomaka Lapaʻau: Ke ʻae ʻia ka hoʻolālā, hoʻonohonoho i ke kaʻina hana a hoʻomaka i ka lāʻau lapaʻau. No nā ʻokiʻoki, aia paha kahi manawa kali no ka loaʻa ʻana o kahi moe. No ka lāʻau lapaʻau, hiki ke hoʻomaka koke ka lāʻau.
• KaʻAnuʻu 7: Ka hahai ʻana a me ka nānā ʻana: E mālama pono i ka papa hana hahai. He mea koʻikoʻi ka nānā mau ʻana e loiloi i ka pane ʻana i ka lāʻau a mālama i nā hopena ʻaoʻao. Hāʻawi ka hapa nui o nā haukapila i nā kahua pūnaewele no nā kūkākūkā hahai.

ʻO ke kuleana o nā hui multidisciplinary (MDT) i ka mālama hou

ʻO ka paʻakikī o ka ma'i 'a'ai ma ke ake koi i ka hana like. ʻO ke kumu hoʻohālike MDT i kēia manawa ke kūlana gula ma ke alakaʻi ʻana i nā haukapila Kina. Ma mua o kaʻikeʻana i kahi kauka hoʻokahi, ua loiloiʻia ka hihia o ka mea maʻi e kahi hui o nā mea akamai mai nāʻano kūikawā likeʻole. Mālama kēia i nā koho lapaʻau āpau ma mua o ka hoʻoholo ʻana.

Hoʻokomo pinepine ʻia ka MDT i nā kauka lapaʻau hepatobiliary, nā kauka oncologists, nā radiologists interventional, radiation oncologists, pathologists, a me nā kahu hānai kūikawā. No ka laʻana, hiki i ke kauka lapaʻau ke aʻo no ka wehe ʻana, ʻoiai ke ʻōlelo nei ka oncologist e hoʻohaʻahaʻa i ka ʻōpū me ka systemic therapy e hoʻomaikaʻi i nā hopena. Hāʻawi ka manaʻo ʻae ʻia e ka MDT i ka mea maʻi i ka hoʻolālā lapaʻau maikaʻi loa i ka ʻepekema a pilikino.

Eia kekahi, maʻalahi nā MDT i ke komo ʻana i nā hoʻokolohua lapaʻau. Me nā halemai e like me ka PLA General Hospital e hana ana ma ke ʻano he GCP, hiki ke ʻike koke ʻia nā poʻe maʻi i kūkākūkā ʻia ma nā hālāwai MDT no ke kākau inoa ʻana i nā hoʻokolohua e hoʻāʻo ana i nā lāʻau hou e like me Finotonlimab a i ʻole nā ​​papa hoʻohui hou. ʻO kēia hoʻohui ʻana o ka noiʻi a me ka hoʻomaʻamaʻa lapaʻau e hoʻolalelale i ka loaʻa ʻana o nā lāʻau lapaʻau hou i ka poʻe i makemake nui iā lākou.

ʻO ka Outlook e hiki mai ana a me nā ʻenehana hou

Ke nānā nei ma mua o 2026, ka wā e hiki mai ana o ka mālama ʻana ka ma'i 'a'ai ma ke ake ʻikea hoʻohiki. Hoʻopili nui ʻia ka noiʻi ʻana i ka lāʻau lapaʻau pololei, kahi e hoʻoponopono ʻia ai nā lāʻau lapaʻau e pili ana i ka genetic makeup o ka maʻi maʻi o ke kanaka. ʻO nā biopsies wai, ka mea e ʻike ai i ka DNA tumo i loko o ke koko, e lilo i mea maʻamau no ka ʻike mua ʻana a me ka nānā ʻana i ka pane ʻana me ka ʻole o nā kaʻina hana invasive.

Ke pāʻani nei ʻo Artificial Intelligence (AI) i kahi hana hoʻololi. Ke hoʻohana nei nā halemai ma Beijing i nā ʻōnaehana diagnostic i kōkua ʻia e AI no ka nānā ʻana i nā scan imaging me ka ʻoi aku ka pololei ma mua o nā maka kanaka wale nō. Hiki i kēia mau ʻōnaehana ke ʻike i nā hōʻailona maʻalahi o ka hoʻi hou ʻana o ka maʻi maʻi a i ʻole ke wānana i ka pane ʻana o kahi maʻi koko i nā lāʻau lapaʻau kūikawā, e kōkua ana i nā kauka i ka hoʻoholo ʻana i ka ʻike.

Eia kekahi, ke hoʻomau nei ka hoʻomohala ʻana o nā immunotherapies e hiki mai ana. Ke ʻimi nei nā mea noiʻi i nā antibodies bispecific a me nā lāʻau lapaʻau cell CAR-T i hoʻolālā ʻia no nā maʻi maʻi paʻa e like me HCC. ʻOiai ka nui o nā hoʻokolohua lapaʻau, paʻa kēia mau ʻenehana i ka hiki ke hoʻomaikaʻi hou i nā helu ola a me ka maikaʻi o ke ola no nā maʻi me ka maʻi holomua.

Ka hopena

Ke hoʻokele nei i kahi hōʻailona o ka ma'i 'a'ai ma ke ake paʻakikī, akā ʻo nā holomua olakino i hoʻokō ʻia e 2026 hāʻawi i ka manaʻolana ʻike ʻole. ʻO Kina, a ʻo Beijing hoʻi, ke kū nei i ke poʻo o kēia holomua, e hāʻawi ana i ke komo ʻana i nā halemai papa honua, nā hui ʻokiʻoki akamai, a me nā lāʻau lapaʻau hou loa. Mai ka hiki ke ho'ōla o ka ʻoki a me ka hoʻololi ʻana i nā pono hoʻonui ola o nā hui immunotherapy hou e like me Lenvatinib me TACE a me Finotonlimab, ʻoi aku ka ikaika o ka arsenal therapeutic ma mua o ka manawa.

Paipai ʻia nā poʻe maʻi e ʻimi i ka mālama ma nā kikowaena kūikawā e hoʻohana ana i ke ala Multidisciplinary Team (MDT) e hōʻoia i ka hoʻomaʻamaʻa piha a pilikino. ʻOiai hiki ke ʻokoʻa nā kumukūʻai, ʻo ka hoʻokomo ʻana i nā lāʻau lapaʻau koʻikoʻi i nā papahana ʻinikua aupuni a me ka loaʻa ʻana o nā koho lapaʻau like ʻole e maʻalahi ka mālama pono. ʻO ka ʻike mua ka mea kaua ikaika loa; ʻO ka hoʻomaʻamaʻa maʻamau no nā poʻe koʻikoʻi hiki ke alakaʻi i ka maʻi ma kahi pae e hiki ai ke mālama ʻia. Me ka hoʻomau hou ʻana a me ka nānā ʻana i ka mea maʻi, ke hoʻomau nei ka manaʻo no nā maʻi maʻi maʻi ate i ka hoʻomaikaʻi ʻana i kēlā me kēia makahiki.